Indianapolis IN and Columbus OH (U.S.A) – 8th April 2020.
Telix Pharmaceuticals (U.S.) Inc. (‘Telix U.S.A’), a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has entered into a definitive commercial agreement with Columbus-based Cardinal Health to provide radiopharmacy and logistics services to support Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.
Under the agreement, Cardinal Health will prepare and deliver patient-specific unit-doses of Telix’s prostate cancer imaging product TLX591-CDx, for the U.S.
Tiffany Olson, President of Cardinal Health’s Nuclear & Precision Health Solutions stated “Cardinal Health has a distinguished history of collaborating with innovators and pharmaceutical companies to help develop and bring to market new advances for the diagnosis and treatment of diseases. Through our continued collaboration with Telix, we are furthering the tools available to diagnose and treat a disease that impacts millions of men across the United States.”
Telix U.S.A President Bernard Lambert stated, “This agreement extends our existing relationship with Cardinal Health to commercial-scale distribution. Cardinal Health is a leading U.S. nuclear pharmacy distribution network and this commercial agreement will enable us to deliver broad patient access to prostate cancer imaging in the U.S.”
About Prostate Cancer Imaging in the U.S. Other than skin cancer, prostate cancer is the most common male cancer in the United States, with approximately 190,000 new cases annually and three million men living with prostate cancer. There remains a major unmet need to better diagnose and stage men with prostate cancer, from initial diagnosis all the way to therapeutic monitoring in patients with late-stage metastatic disease. U.S. prostate imaging is estimated to be a $500 million market opportunity, with a leading position for the use of Positron Emission Tomography (PET) and imaging agents targeting prostate-specific membrane antigen (PSMA) in particular.
About Telix’s prostate cancer imaging product (TLX591-CDx) TLX591-CDx (kit for the preparation of 68Ga-PSMA-11) is a proprietary formulation of PSMA- HBED-CC (PSMA-11), a novel small molecule agent targeting prostate-specific membrane antigen (PSMA), originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ). The “cold kit” format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, ideally suited for the radiopharmacy setting. TLX591-CDx is available for investigational use only as part of an FDA Investigational New Drug (IND) application. TLX591-CDx is not an FDA-approved agent.
About Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.